-

01:02:42 AM

BCDA Stock News

BCDA - BioCardia Inc.

02/01/23 6:30 AM

Nasdaq : BCDA

low float

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair

RHEA-AI

very positive

12/22/22 7:00 AM

Nasdaq : BCDA

low float

BioCardia Letter to Shareholders

BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders, BioCardia is now

RHEA-AI

neutral

12/15/22 7:00 AM

Nasdaq : BCDA

low float

BioCardia Announces $3.6 Million Private Placement of Common Stock

BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration

RHEA-AI

neutral

12/06/22 7:00 AM

Nasdaq : BCDA

fda approvallow float

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration approval of its Investigational New Drug application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive allogeneic human...

RHEA-AI

neutral

11/09/22 4:05 PM

Nasdaq : BCDA

earningslow float

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on

RHEA-AI

positive

11/02/22 5:31 PM

Nasdaq : BCDA

conferencesearningslow float

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

BioCardia ®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended

RHEA-AI

neutral

10/03/22 7:00 AM

Nasdaq : BCDA

low float

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary

RHEA-AI

neutral

09/14/22 7:00 AM

Nasdaq : BCDA

low float

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that new data from its

RHEA-AI

neutral

09/09/22 7:00 AM

Nasdaq : BCDA

low float

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held on September 12-14, 2022. The in-person venue for the

RHEA-AI

neutral

09/08/22 7:00 AM

Nasdaq : BCDA

conferenceslow float

BioCardia to Participate in Cantor Fitzgerald’s Cell and Genetic Medicines Conference

BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald’s Cell and Genetic Medicines Conference. The conference is being held in person on September 15, 2022, at the Lotte

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

BCDA Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.biocardia.com
CeoPeter Altman
Security nameBioCardia Inc.
Issue typecs
SectorManufacturing
Sic code3842
Employees32
Tags
- Biotechnology
- Health Technology
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address125 Shoreway Rd Ste B
StateCalifornia
CitySan Carlos
Zip94070-2718
CountryUS
Phone16502260120

About BioCardia Inc.

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.